STOCK H2az2^{Tg(Wnt1-cre)11Rth} Tg(Wnt1-GAL4)11Rth/MileJ

Stock number: 007807
Product name: Wnt-1/GAL4/cre-11
Research areas: Neurobiology Research, Research Tools

Description

In 2011, Stock No. 007807 at The Jackson Laboratory Repository was confirmed to harbor the expected Wnt1-Cre transgene, as well as the originally co-injected Wnt1-GAL4 transgene. Because it is redundant to Stock No. 003829, Stock No. 007807 has been terminated.

Detailed description

In 2011, Stock No. 007807 at The Jackson Laboratory Repository was confirmed to harbor the expected Wnt1-Cre transgene, as well as the originally co-injected Wnt1-GAL4 transgene. Because it is redundant to Stock No. 003829, Stock No. 007807 was terminated. The strain phenotype description below has been updated accordingly.

When homozygous for both co-injected transgenes, Wnt-1/GAL4/cre-11 transgenic mice are viable, fertile, normal in size and do not display any gross physical abnormalities. Of note for Stock No. 007807, the donating investigator (Dr. Epstein) reports that homozygous mice may be lethal as some offspring from transgenic parents die around two months of age. Both Cre recombinase and the GAL4 transcriptional activator are expressed under the direction of wingless-related MMTV integration site 1 (Wnt1) promoter/regulatory sequences. Cre recombinase activity is detected in the Wnt1 pattern of expression: in the midbrain by 8.5 dpc and, after neural tube closure, in the dorsal and ventral midlines of the midbrain and caudal diencephalon, midbrain-hindbrain junction and dorsal spinal cord. When Wnt-1/GAL4/cre-11 transgenic mice are bred to mice containing loxP site-flanked sequences, cre-mediated recombination results in deletion of the floxed sequences in the midbrain and developing neural tube of the resulting offspring.

In an attempt to offer alleles on well-characterized or multiple genetic backgrounds, alleles are frequently moved to a genetic background different from that on which an allele was first characterized. This is the case for the strain above. It should be noted that the phenotype could vary from that originally described. We will modify the strain description if necessary as published results become available.

Development

In 2011, Stock No. 007807 at The Jackson Laboratory Repository was confirmed to harbor the expected Wnt1-Cre transgene, as well as the originally co-injected Wnt1-GAL4 transgene. Because it is redundant to Stock No. 003829, Stock No. 007807 was terminated. The strain development description below has been updated accordingly.

The transgenic line Wnt-1/GAL4/cre-11 was created by Dr. David H. Rowitch and Andrew P. McMahon (Harvard University). These mice resulted from co-injection of both the pWEXP2-GAL4 transgene (Wnt1-GAL4) and the pWEXP3C-cre transgene (Wnt1-Cre) into the pronuclei of B6CBAF1/J (C57BL/6JxCBA/J) zygotes. Double transgenic mice from founder line 11 were obtained and bred with Swiss outbred mice. Some Wnt-1/GAL4/cre-11 transgenic mice were sent to Dr. Miles Epstein (University of Wisconsin - Madison). At that time they were reported to be on a C57BL/6J genetic background (although they were white). Dr. Epstein bred Wnt-1/GAL4/cre-11 transgenic mice together for many generations. In 2009, Dr. Epstein sent Wnt-1/GAL4/cre-11 transgenic mice, now with brown coat color, to The Jackson Laboratory Repository in 2009 (as Stock No. 007807). Upon arrival, mice were bred to C57BL/6J inbred mice (Stock No. 000664) for at least one generation to establish the colony. The description of each transgene is below.

The pWEXP2-GAL4 transgene (Wnt1-GAL4) was designed by Dr. David H. Rowitch and Andrew P. McMahon (Harvard University) with the mouse Wnt1 promoter/enhancer elements upstream of a sequence encoding the full-length yeast GAL4 gene. Specifically, the Wnt1-GAL4 transgene was created by inserting a sequence encoding the full-length yeast GAL4 gene into a 10 kbp modified mouse Wnt1 genomic sequence at a polylinker site between the promoter and enhancer (the Wnt1 genomic sequence spans from approximately 1 kbp upstream of the translation initiation codon to approximately 5.5 kbp downstream of the polyA signal, and is modified with a polylinker that disrupts the translational start site and a reverse-oriented neo cassette in 3' UTR of exon 4).

The pWEXP3C-cre transgene (Wnt1-Cre) was designed by Dr. David H. Rowitch and Andrew P. McMahon (Harvard University) with the mouse Wnt1 promoter/enhancer elements upstream of a Cre recombinase cDNA sequence. Specifically, the Wnt1-Cre transgene was created by inserting the Cre recombinase cDNA into a 10 kbp modified mouse Wnt1 genomic sequence at a polylinker site between the promoter and enhancer (the Wnt1 genomic sequence spans from approximately 1 kbp upstream of the translation initiation codon to approximately 5.5 kbp downstream of the polyA signal, and is modified with a polylinker that disrupts the translational start site and a reverse-oriented neo cassette in 3' UTR of exon 4).

Allele

Symbol: Tg(Wnt1-GAL4)11Rth
Name: transgene insertion 11, David H Rowitch
MGI accession ID: MGI:3524966
Generation method: Transgenic
Attributes: Inserted expressed sequence
Marker symbol: Tg(Wnt1-GAL4)11Rth
Marker name: transgene insertion 11, David H Rowitch
Chromosome: UN
Strain of origin: (C57BL/6J x CBA/J)F1
Expressed genes: GAL4,transcriptional activator GAL4,yeast
Site of expression: embryonic neural tube, midbrain, dorsal and ventral midlines of the midbrain and caudal diencephalon, the mid-hindbrain junction and dorsal spinal cord
Molecular note: The transgene contains the yeast GAL4 gene directed by Wnt1 promoter/enhancer sequences. Expression of the transgene matches that of the endogenous Wnt1.
General note: Six lines were generated.

Homozygous transgenic mice that are also homozygous for Tg(Wnt1-cre)11Rth are viable, fertile, normal in size, and do not display any gross physical or behavioral abnormalities. Both Cre recombinase and the GAL4 transcriptional activator are expressed under the direction of Wnt1 regulatory sequences. Regulated expression initially occurs in the midbrain. After neural tube closure, expression occurs in the dorsal and ventral midlines of the midbrain and caudal diencephalon, the midbrain-hindbrain junction, and in the dorsal spinal cord.

Allele

Symbol: H2az2^{Tg(Wnt1-cre)11Rth}
Name: transgene insertion 11, David H Rowitch
MGI accession ID: MGI:2386570
Generation method: Transgenic
Attributes: Recombinase-expressing
Marker symbol: H2az2
Marker name: H2A.Z histone variant 2
Chromosome: 11
Strain of origin: (C57BL/6J x CBA/J)F1/J
Expressed genes: cre,cre recombinase,bacteriophage P1
Site of expression: embryonic neural tube, midbrain, dorsal and ventral midlines of the midbrain and caudal diencephalon, the mid-hindbrain junction and dorsal spinal cord
Molecular note: The Wnt1 promoter preceded the cre recombinase coding sequence which was followed downstream by the Wnt1 enhancer. The Wnt1 regulatory sequences initially direct expression in the midbrain. After neural tube closure, expression occurs in the dorsal and ventral midlines of the midbrain and caudal diencephalon, the midbrain-hindbrain junction and in the dorsal spinal cord. Line 11 inserted into the gene at 6425500-6456783 (Build GRCm38/mm10) resulting in a 31,283 bp deletion. Founder line x has a copy number of greater than 5.
General note: Homozygous transgenic mice that are also homozygous for Tg(Wnt1-GAL4)11Rth are viable, fertile, normal in size, and do not display any gross physical or behavioral abnormalities.